Latest Healthcare News

Page 15 of 197
Memphasys will receive an A$3.5 million advance from major shareholder Peters Investments to expand Felix production, inventory and sales capacity as repeat orders emerge across international markets. The funding carries a 12.5% interest rate, potential equity dilution and requires shareholder and ASX approvals before the convertible notes can be issued.
Ada Torres
Ada Torres
29 Sept 2026
Stakk has secured a live signature verification engagement for use by the United States Federal Bureau of Investigation through ParaScript, with the agreement running to December 2027. The company says the contract will contribute meaningfully to its FY2027 revenue target, now expected to exceed $55 million, although its value remains confidential.
Sophie Babbage
Sophie Babbage
29 Sept 2026
Cochlear is defending a class action filed in the Supreme Court of Victoria over its FY26 underlying net profit forecast. The claim covers investors who acquired interests in Cochlear shares between 15 August 2025 and 21 April 2026.
Ada Torres
Ada Torres
29 Sept 2026
Firebrick Pharma has approved a phased push into US retail pharmacies after Nasodine online sales grew by more than 200% in FY26. Up to six regional pharmacy groups representing about 700 stores have expressed strong interest in early orders, although no binding orders have been disclosed.
Ada Torres
Ada Torres
29 Sept 2026
Embelton Limited (ASX:EMB) grew revenue, profit and operating cash flow in FY2026 despite subdued residential construction, while maintaining its 35-cent fully franked annual dividend. The flooring and engineering group is leaning further into infrastructure, data centres, healthcare and other commercial work, although its near-term contracting pipeline remains modest.
Victor Sage
Victor Sage
28 Sept 2026
Paradigm Biopharmaceuticals will keep its ASX securities suspended until at least 30 September while it reviews interim Phase 3 data and assesses the operational and financial consequences. The company also remains in discussions with Obsidian Global GP, LLC, but has not disclosed the trial results or their direction.
Ada Torres
Ada Torres
28 Sept 2026
Enlitic has secured a US$806,000 contract to migrate 10.6 million medical imaging studies for University of Michigan Health-Sparrow. The project also gives its Ensight platform a first active integration with Sectra’s enterprise imaging environment.
Victor Sage
Victor Sage
28 Sept 2026
Marlin Global’s portfolio fell 6.3% before fees and tax in FY26 while its benchmark gained 30.5%, producing a NZ$17.3 million net loss. The Fisher Funds-managed vehicle is responding with broader sector coverage, faster portfolio turnover and an expanded research team.
Victor Sage
Victor Sage
28 Sept 2026
Barramundi Limited (NZX:BRM) has reported the worst performance in its 20-year history, with a NZ$42.9 million net loss and a 17.0% fall in gross portfolio performance. The board is reviewing Fisher Funds’ management performance just weeks before its five-year agreement comes up for renewal.
Claire Turing
Claire Turing
28 Sept 2026
Nexsen has proposed a 50:50 joint venture with FlashDx Shenzhen to develop and commercialise an enhanced molecular Group B Streptococcus test, using an existing CE-marked platform as its starting point. The proposed venture could shorten Nexsen’s path into hospital and intrapartum testing across Asia-Pacific, but the term sheet remains non-binding and regulatory work is still ahead.
Victor Sage
Victor Sage
25 Sept 2026
Memphasys says it has identified a potential FDA 510(k) pathway for its Felix sperm separation system, replacing the more complex De Novo route previously contemplated. The company will seek FDA feedback before targeting a formal submission in the first quarter of 2027, while keeping commercial execution focused on existing markets.
Ada Torres
Ada Torres
25 Sept 2026
Betashares’ newly launched FTSE Global Infrastructure Shares Currency Hedged ETF reported $1.204 billion in profit and $8.08 billion in net assets for its first reporting year. The audited results also show strong gains across several established funds, alongside sharp post-year-end NAV movements in energy and gold miners.
Claire Turing
Claire Turing
25 Sept 2026

Browse the archive

Full archive